July 1, 2026 – Citeline (a Norstella Group company), which provides insights for the pharmaceutical and biopharmaceutical industries, has released the "Clinical Trials 2025 Annual Review," summarizing clinical trial trends in 2025. A "Clinical Trials 2025 Annual Review Japanese Summary Edition," compiling key points, has also been published. ■ Key Findings 2025 saw a decrease in the total number of clinical trials, but an improvement in success rates and quality of late-stage trials, marking a year of structural transformation from "quantity to quality." Completed trials decreased by 11% year-on-year to 4,364 Success rates improved Oncology remains the largest therapeutic area Metabolic and endocrine disorders entered the top 3 for the first time GLP-1 related research expanded (focusing on obesity and type 2 diabetes) Infectious disease and vaccine trials decreased (post-pandemic shifts) Pipelines expanded, with an increase in novel mechanisms of action *Source: Citeline, “Annual Completed Clinical Trials Report 2026 Edition” (Analysis of 2025 performance) ■ Implications for the Industry Despite a 11% year-on-year decrease in clinical trial numbers in 2025, the industry demonstrated a trend towards "quality over quantity," with rising success rates and an increase in positive pivotal trials. Furthermore, pipeline expansion is progressing, particularly in oncology and metabolic/endocrine areas, confirming advancements in the development of new medicines. On the other hand, regulatory changes, funding environments, and geopolitical factors are influencing clinical trial activities, and these external factors may impact future trends. *The content herein is an extraction of publicly available information from the report and analysis/consideration based on our database, and does not guarantee future results or market trends. Interpretation may also involve certain assumptions and limitations. ■ Clinical Trials 2025 Annual Review Japanese Summary Edition Access the Japa